Bhagiradha Chemicals & Industries Ltd

Action details

• Agency: India Ratings and Research (Ind-Ra).
• Bank loan facilities of INR 6,000 million rated IND BBB+/Stable/IND A2+.
• Rating assigned to Bheema Fine Chemicals Private Limited, BCIL subsidiary.

Rationale & linkage

• Top-down view due to BCIL linkages and unconditional corporate guarantee.
• BFCPL central to BCIL's growth with 9,000 mtpa expansion.
• Consolidated metrics supported by equity infusion and phased capex.
• Liquidity deemed adequate with sanctioned limits and capex moratorium.
• Risks: elevated leverage, working capital intensity, regulatory risk, product concentration.

Financials & leverage

• Phase I capacity 4,500 mtpa commissioned December 2025; ramp-up ongoing.
• FY26 revenue INR 5,359m; EBITDA INR 571m; EBITDA margin 10.7%.
• Debt at FYE26 INR 2,600m; net leverage 4.3x; interest coverage 3.3x.

Liquidity & sensitivities

• Cash and equivalents INR 163.5m at FYE26; capex funding via internal accruals.
• Peak net leverage projected near 5.0x in FY28; coverage ~3.3x-4.8x.
• Positive: upgrade if BCIL linkage improves; Negative: downgrade if linkage weakens.
• Outlook: Stable.

Meeting Details

• Date & Time: 14 August 2026, 10:00 am onwards
• Type/Mode: 1x1 and group meetings, venue Mumbai
• Organised by: Equirus Annual India Conference
• Place: Mumbai

Participants

• Company officials/management to attend; specific roles not disclosed

Purpose

• Discussions based on publicly available information; UPSI not discussed

Additional Notes

• Presentation materials to be available on company website

AGM details

• Date and time: 31 July 2026 at 11:00 a.m.; VC/OAVM; concluded 11:37 a.m.
• Record date 23 Jul 2026; record shareholders 13,271; attendees: 3 promoters, 75 public.
• AGM held for the company’s 33rd year.

Key resolutions and outcomes

• Resolution 1: Adopt Audited Standalone Financial Statements for year ended 31 March 2026; passed.
• Resolution 2: Final dividend of Rs 0.15 per share (Re 1 face) at 15%; approved.
• Resolution 3: Independent director Shri Nresh Kumar Soman re-appointed by rotation; approved.
• Resolution 4: Ratify remuneration of Cost Auditors for 2026-27; Rs 1.50 lakh per annum plus GST and expenses; approved.

Directors and auditors

• Independent director Shri Nresh Kumar Soman re-appointed by rotation (DIN 00031096).
• Remuneration of Cost Auditors ratified for 2026-27; Rs 1.50 lakh per annum plus GST.

AGM Details

• Held on 31 July 2026 at 11:00 AM via VC/OAVM from Hyderabad.
• Concluded at 11:37 AM.
• Remote e-voting conducted 27–30 July 2026.

Resolutions put to vote

• Ordinary: Adoption of standalone and consolidated financial statements for FY ended 31 March 2026.
• Ordinary: Declaration of final dividend of 15% (₹0.15 per share).
• Ordinary: Re-appointment of director retiring by rotation.
• Ordinary: Ratification of remuneration of Cost Auditors for FY 2026-27.

Voting outcome

• All resolutions passed with requisite majority.

Dividend

• Final dividend approved at 15% (₹0.15 per share).

Directors

• Director retiring by rotation re-appointed.

Auditors

• Statutory auditors attended; remuneration of Cost Auditors for FY 2026-27 ratified.

Other notes

• AGM held via VC/OAVM with NSDL for e-voting; results to be posted on exchanges and company site.

AGM notice and AR access

• 33rd AGM to be held on July 31, 2026 at 11:00 IST via VC/OAVM.
• Annual Report for FY 2025-26 available online; AR link provided.
• Shareholders with unregistered emails advised to update address with RTA/depository.
• KYC requirements include PAN, postal address, email, mobile, and bank details.
• Cut-off date for email update: July 3, 2026.
• RTA for updates: XL Softech Systems Limited (contact emails provided).
• AR link: https://www.bhagirad.com/wp-content/uploads/2026/07/ar2026.pdf

AGM details

• 33rd AGM on Friday, July 31, 2026, at 11:00 a.m. IST via VC/OAVM.
• Record date for dividend eligibility: July 24–31, 2026.
• Cut-off date for voting: July 23, 2026.
• Remote e-voting window: July 27–30, 2026.

Resolutions proposed

• Ordinary: Adopt standalone financial statements for FY2025-26.
• Ordinary: Adopt consolidated financial statements for FY2025-26.
• Ordinary: Declare final dividend of 15% (₹0.15) per share.
• Ordinary: Re-appoint Suresh Kumar Somani as Director.
• Special: Ratify cost auditors’ remuneration for FY2026-27 at ₹1,25,000.

Dividend

• Final dividend proposed at 15% (₹0.15 per share).

Director changes

• Re-appointment of Sri Suresh Kumar Somani as Director (Non-Executive Non-Independent).
• Remuneration last drawn NIL; sitting fees to be paid.

Cost audit

• Cost Auditor remuneration for FY2026-27 fixed at ₹1,25,000; to be ratified.

Financial performance

• Consolidated revenue ₹535.94 Cr, up 21.7% YoY.
• Consolidated EBITDA ₹59.50 Cr; margin about 11%.
• Consolidated PAT ₹18.17 Cr; growth vs prior year.
• Standalone revenue ₹521.22 Cr; EBITDA ₹55.35 Cr; PAT ₹26.24 Cr.
• Standalone EPS ₹2.02; Consolidated EPS ₹1.40.
• Cash profit ₹44 Cr for FY26.

Growth & operations

• Bheema Phase I complete; Phase II capex ≈₹400 Cr; completion FY27-28.
• Bheema utilisation ≈35% in FY26; target 9,002 MT pa post-expansion.
• Solar plant 4 MW commissioned Apr 2025; power costs reduced.
• Top five products contributed 81% of FY26 revenue (vs 85% FY25).
• Active customers reached 149; up from 98 in FY21; five-year growth ~52%.
• CM/CDMO expansion with global partners; deeper backward integration improves margins.

R&D & product portfolio

• 3 new molecules launched in FY26; portfolio now 35 molecules.
• GoI-recognised R&D centre at Ongole; core growth engine.
• Azoxystrobin backward integration to N-7; progress toward N-9.
• Fipronil deep integration; domestic market share about 27%.

Debt & liquidity

• Total borrowings ₹23,151.02 lakh; cash ₹16.35 Cr.
• Net debt to equity ratio ~0.30x.
• Convertible warrants raised ₹341.18 Cr; fully utilized by June 2025.
• 4 MW solar plant installed; energy costs reduced.
• Authorized share capital increased to ₹85 Cr; 12.96 Cr shares issued.

Dividend & capital allocation

• Final dividend proposed ₹0.15 per share (15%).
• Register closure for dividend eligibility: 24–31 July 2026.
• No unclaimed dividend transferred to IEPF in FY26.
• 25,61,425 warrants converted; equity shares issued.
• Share capital unchanged; 12.96 Cr shares outstanding.

Governance & board changes

• Kishor Shah reappointed Independent Director for 5 years (2025–2030).
• Dr. G. Aruna reappointed Independent Woman Director (2025–2030).
• Chandra Sekhar Singavarapu reappointed MD (2025–2030).
• Suresh Kumar Somani appointed Non-Executive Non-Independent (May 2025).
• Lalitha Sree Singavarapu ceased May 28, 2025.
• CFO change: B. Krishna Mohan Rao retired Feb 28, 2026; Ranjit Kumar Kilaru appointed Mar 1, 2026.
• FY26 board meetings: 5; independent director meetings May 28, 2025 and Feb 10, 2026.

CSR & ESG highlights

• CSR spend ₹89.50 L; 2% of avg net profit ₹89.41 L.
• CSR beneficiaries: Rural 1,250; Education 1,535; Health care 7,756.
• CSR policy available on company website; strong governance & sustainability focus.
• Zero Liquid Discharge; 4 MW solar; extensive waste management & environmental controls.

AGM & disclosures

• 33rd AGM on Fri, 31 Jul 2026 at 11:00 IST via VC/OAVM.
• Annual Report & AGM Notice available on company website and stock exchanges.
• Remote e-voting window: 27–30 Jul 2026; cut-off 23 Jul 2026.
• Record date for dividend: 3 Jul 2026.

Outlook & risks

• Industry headwinds persist: volatile raw materials, currency, and regulatory changes.
• India remains a fast-growing agrochemical hub; ramp-up at Bheema supports revenue growth.

Dematerialisation status

• Dematerialisation requests received during quarter ended 30 June 2026 were confirmed to depositories.
• Securities dematerialised have been listed on the stock exchange where the earlier issued securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled after verification; depository name substituted within 15 days.